University of California
Aveo Oncology's Ficlatuzumab Improves Response, Survival for AML Patients, Study Finds
The study also identified high HGF expression and p-S6 suppression as biomarkers of resistance and response, respectively.
BridgeBio Rolls Out New Academic Pacts to Advance Precision Oncology Programs
The firm is collaborating with multiple institutions to support translational research and speed up insights into biomarker-driven cancer treatments.
Researchers are increasingly arguing that the tissue-agnostic approval was too broad, and that tumor mutational burden is only a biomarker of response to immunotherapy in a handful of cancer types.
Taproot Health, Five Cancer Centers Agree to Conduct Precision Oncology Master Trial, Share Data
Within the master observational trial, the organizations have agreed to prospectively collect real world data and ultimately build a national oncology database.